EyePoint Pharmaceuticals reported a net loss of $11.6 million, or $0.12 per share, for the quarter ended Dec. 31, 2018, compared with a net loss of $5.8 million, or $0.13 per share, in the same quarter of 2017, according to a press release.
Operating expenses for the quarter increased from $6.7 million to $13.4 million. Research and development costs decreased from $4.3 million to $4.2 million, and general and administrative costs grew from $2.5 million to $4.7 million. Sales and marketing expenses for the quarter were $4.5 million compared with (Read more...)
Uncategorized